Clinical trials: Osteoporosis Postmenopausal
Osteopenia, Osteoporosis
Effects of Physical Exercise on Postmenopausal Risk Factors in Women With Osteopenia
Menopause usually have a serious impact on a woman's life, associated with negative consequences for health and quality of life.
- Trial name
- ACTLIFE (NCT03959995)
- Testing
- High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT), Wellness
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Osteoporosis
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
The purpose of this study is to assess the effects of zoledronic acid administered at the same time with teriparatide compared to zoledronic acid alone and teriparatide alone on bone mineral density (BMD) gain in the lumbar spine…
- Trial name
- NCT00439244
- Testing
- Zoledronic acid, Teriparatide
- Where
- 33 sites in United States, Belgium and 2 more
- Volunteers
- 412 people
- Sponsor
- Novartis
Postmenopausal Osteoporosis
Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
A 2-year, Multicenter, Open-label, Phase IIIb Extension Study to Assess Bone Mineral Density and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women with Postmenopausal Osteoporosis Who Sequentially Completed…
- Trial name
- NCT00577421
- Testing
- risedronate
- Where
- 5 sites in Australia, Italy and 3 more
- Volunteers
- 32 people
- Sponsor
- Warner Chilcott
Osteoporosis
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
This is an 18-month, double-blind, placebo-controlled, Phase III trial with a 12-month interim analysis of the effect of ALX1-11, recombinant human parathyroid hormone (1-84) (rhPTH [1-84]), on fracture incidence in women with…
- Trial name
- NCT00172081
- Testing
- ALX1-11
- Where
- 174 sites in United States, Argentina and 7 more
- Volunteers
- 2,532 people
- Sponsor
- Shire
Osteoporosis, Postmenopausal
A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
The purpose of this study is to evaluate the tolerability of two different formulations of blosozumab in women who have reached menopause. This study will last approximately 12 weeks for each participant, not including screening.
- Trial name
- NCT02337387
- Testing
- Blosozumab
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Post Menopausal Osteoporosis
Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France
The purpose of the study is to describe the characteristics and management of post menopausal women with osteoporosis treated with Prolia in France, and examine the use of Prolia in routine clinical practice in France
- Trial name
- PILOTE (NCT02347865)
- Testing
- AMG 162 - Prolia
- Where
- France
- Volunteers
- 777 people
- Sponsor
- Amgen
Osteopenia
A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis
The primary purpose of this study was to evaluate the efficacy of oral calcitonin (rsCT)tablets in the prevention of bone loss in postmenopausal women with lower bone mineral density at increased risk of fracture.
- Trial name
- NCT01292187
- Testing
- Oral calcitonin at dinnertime, Oral calcitonin at bedtime
- Where
- 10 sites in United States
- Volunteers
- 129 people
- Sponsor
- Tarsa Therapeutics, Inc.
Osteoporosis, Humoral Hypercalcemia of Malignancy
One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, that can be given safely over one week.
- Conditions
- Osteoporosis, Humoral Hypercalcemia of Malignancy, Hyperparathyroidism
- Trial name
- NCT00580788
- Testing
- PTHrP (1-36)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Osteoporosis, Postmenopausal
Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes
Compare the data obtained with two formulations of alendronate 70 mg (tablets vs effervescent tablet for buffered solution) on the change in bone turnover markers, on gastric tolerance and on treatment adherence (including…
- Trial name
- NCT03435094
- Testing
- Binosto 70Mg Effervescent Tablet, Fosamax 70Mg Tablet
- Where
- 2 sites in Switzerland
- Volunteers
- 80 people
- Sponsor
- Labatec Pharma SA
Bone Density, Osteopenia
The Influence of Vibration on Bone Mineral Density in Women Who Have Weak Bones After Menopause
This study will examine whether whole-body vibration slows down bone loss in healthy postmenopausal women with osteopenia. Whole-body vibration is a promising novel therapy that involves standing on a platform which produces…
- Conditions
- Bone Density, Osteopenia, Osteoporosis, Post-Menopause
- Trial name
- NCT00420940
- Testing
- Juvent 1000 Dynamic Motion Therapy (DMT) Platform
- Where
- Canada
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Osteoporosis
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women
The purpose of this study is to compare the efficacy and safety of Denosumab 60 mg produced by AryoGen Pharmed and Amgen Denosumab 60 mg among osteoporotic postmenopausal women.
- Trial name
- NCT03293108
- Testing
- Denosumab, calcium, vitamin D
- Where
- Iran
- Volunteers
- 190 people
- Sponsor
- AryoGen Pharmed Co.
Postmenopausal Women With Osteoporosis
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.
- Trial name
- NCT06898060
- Testing
- QLG2128, Teriparatide Injection
- Volunteers
- 282 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Osteopenia
Effectiveness of Calcium and Vitamin D, With and Without Collagen Peptide, in Enhancing Bone Mineral Density on Postmenopausal Women With Osteopenia
Osteopenia is characterized by bone mineral density (BMD) being lower than normal but not reaching the osteoporosis threshold, poses a serious problem for women after menopause.
- Trial name
- NCT06464718
- Testing
- Fortibone, Chewable Tablet
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- Frontier Medical and Dental College, Abbotabad
Postmenopausal Disorder
B-cryptoxanthin and Phytosterols on Bone Remodeling and Cardiovascular Risk Factors
We, the investigators, aim to study, in vitro and in vivo, the bioavailability of added b-cryptoxanthin and phytosterols and evaluate in vivo its effect on biochemical markers of bone remodelling and cardiovascular risk.
- Trial name
- NCT01074723
- Testing
- b-cryptoxanthin and phytosterols
- Where
- Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Puerta de Hierro University Hospital
Osteoporosis
To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women
The purpose of this study is to evaluate the Efficacy and the Safety of Monthly(RisenexM group) versus Weekly Oral risedronate(Risenexsplus group) in Korean postmenopausal osteoporotic women(Phase IV)
- Trial name
- NCT01904110
- Testing
- Risedronate/Cholecalciferol combination(montly), Risedronate/Cholecalciferol combination(weekly)
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Osteoporosis
Effects of Continuous Combined Hormone Replacement Therapy and Clodronate on Bone Mineral Density (BMD) in Osteoporotic Women
Recent studies suggest that the combination of two inhibitors of bone resorption may induce a greater increase in bone mineral density (BMD) than either agent alone.
- Trial name
- Osteo (NCT00877097)
- Testing
- Klodronate and Kliogest, Bonefos
- Volunteers
- 167 people
- Sponsor
- Kuopio University Hospital